CPI set to open new centre for cutting-edge medicines manufacturing in Scotland

CPI is set to create a new centre of excellence for manufacturing cutting-edge medicines after a multi-million-pound fund was announced.

The Oligonucleotide Manufacturing Innovation Centre of Excellence will focus on developing innovative and sustainable manufacturing techniques in an emerging area of medicine known as oligonucleotides.

What are Oligonucleotides?

Oligonucleotides are a revolutionary new therapeutic in the pharma industry. These short, chemically synthesised fragments of DNA or RNA modulate protein expression through several different mechanisms to treat the underlying drivers of disease.

They can cover a wide variety of diseases, from cancer to Alzheimer’s, and have the potential to unlock medicines for conditions currently considered untreatable and create more effective medicines for larger patient populations such as heart disease.

The Centre will be the second facility opened by CPI within the Advanced Manufacturing Innovation District Scotland (AMIDS). This new Centre will build on millions of pounds of investment currently being delivered through the Medicines Manufacturing Innovation Centre.